Ono Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Ono Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ono Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ono Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is an immuno-oncology company that provides research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. The company's product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma, and allergic rhinitis, among others for the treatment of cancer. The company also offers products in various formulations such as capsules, patches, dry syrup, tablets, injections, and intravenous infusions. Ono Pharmaceutical has manufacturing facilities, including the Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
Headquarters
Japan
Address
1-8-2, Kyutaro-Machi, Chuo-Ku, Osaka, 541-8564
Website
www.ono-pharma.com/ja
Telephone
81 6 62635670
No of Employees
4,206
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4528 (TYO)
Revenue (2025)
$3.3B
5.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
39.4%
(2025 vs 2024)
Market Cap*
$7.4B
Net Profit Margin (2025)
XYZ
31.6%
(2025 vs 2024)
* As of and is in US$
Ono Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Foipan Tablets | Services | Glactiv |
| Glactiv Tablets | Supply | FORXIGA |
| Kinedak Tablets | Marketing | Recalbon |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company entered into an agreement with Congruence Therapeutics to discover novel small-molecule modulators against multiple protein targets in neurology and immunology. |
| 2026 | Contracts/Agreements | In March, the company entered into an agreement with Daito Pharmaceutical to transfer the manufacturing and marketing approval authorization for Opalmon Tablets 5 μg and Prostandin Ointment. |
| 2026 | Contracts/Agreements | In January, the company signed a license and research agreement with Scenic Biotech to use Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. |
Competitor Comparison
| Key Parameters | Ono Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Shionogi & Co Ltd | Kyowa Kirin Co Ltd | Sumitomo Pharma Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka | Chuo-Ku | Osaka | Chiyoda-Ku | Osaka |
| State/Province | Osaka | Tokyo | Osaka | Tokyo | Osaka |
| No. of Employees | 4,206 | 7,872 | 4,959 | 5,161 | 3,832 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Akira Sagara | Chairman; Chief Executive Officer | Executive Board | 2024 | 68 |
| Takino Juichi | Chief Operating Officer; President; Director | Executive Board | - | 58 |
| Satoshi Takahagi | Director; Senior Managing Executive Officer | Executive Board | 2025 | 62 |
| Harumi Nakano | General Manager - Finance and Accounting; Executive Officer | Senior Management | 2026 | - |
| Yamada Takehiro | Executive Officer; Head - Risk and Compliance Management | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer